Eli Agassi
About Eli Agassi
Eli Agassi is a Senior Safety Officer with extensive experience in pharmacovigilance, currently leading safety initiatives at Nutrasource since 2019. He has a background in pharmacy and business administration, and has worked with various organizations including Health Canada and Sanofi.
Work at Nutrasource
Eli Agassi has been serving as a Senior Safety Officer at Nutrasource since 2019. In this role, he leads the safety team in signal detection and risk minimization efforts. His responsibilities include developing pharmacovigilance processes for both clinical and post-marketing activities. Agassi utilizes his expertise to manage safety information across a diverse range of products, ensuring compliance with safety regulations.
Previous Experience at Health Canada
Prior to his current position, Eli Agassi worked at Health Canada | Santé Canada as a member of the Canada Vigilance Expert Working Group from 2011 to 2014. During this three-year tenure, he contributed to the assessment and management of safety information related to health products, enhancing the safety monitoring framework in Canada.
Education and Expertise
Eli Agassi holds a Bachelor of Science (B.Sc.) in Pharmacy from The Hebrew University. He further advanced his education by obtaining a Master of Business Administration (MBA) from the University of the People. His academic background supports his expertise in pharmacovigilance, where he is experienced in using databases such as ARGUS and ARISg, as well as the Medrio clinical database.
Career at Sanofi
Eli Agassi has extensive experience at Sanofi, where he held multiple roles over a span of 10 years. He started as a Case Analyst in Pharmacovigilance from 2006 to 2008, then served as a Reporting Officer from 2008 to 2016, and later as a Case Management Regulatory Expert from 2016 to 2019. In these positions, he specialized in managing safety information, authoring reports, and conducting regulatory inquiries.
Pharmacovigilance Skills
Agassi possesses in-depth knowledge of safety regulations and guidance from various international regulatory bodies, including the FDA, Health Canada, EMA, and ICH. He acts as a Subject Matter Expert (SME) in safety aspects such as medical coding, causality assessment, and regulatory inquiries, demonstrating his comprehensive understanding of the pharmacovigilance landscape.